Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16408545 | 1.00 | SIGMAR1 (0.75) | SIGMAR1TMEM97 | |
| SCHEMBL18099233 | 0.93 | SIGMAR1 (0.69) | SIGMAR1TMEM97 | |
| SCHEMBL18099351 | 0.93 | SIGMAR1 (0.69) | SIGMAR1TMEM97 | |
| SCHEMBL18100591 | 0.90 | SIGMAR1 (0.80) | SIGMAR1TMEM97 | |
| SCHEMBL16408551 | 0.90 | SIGMAR1 (0.80) | SIGMAR1TMEM97 | |
| SCHEMBL16408553 | 0.90 | SIGMAR1 (0.66) | SIGMAR1TMEM97 | |
| SCHEMBL16397789 | 0.90 | SIGMAR1 (0.80) | SIGMAR1TMEM97 | |
| SCHEMBL18099313 | 0.87 | SIGMAR1 (0.65) | SIGMAR1TMEM97 | |
| SCHEMBL18099340 | 0.86 | SIGMAR1 (1.00) | SIGMAR1TMEM97 | |
| SCHEMBL21499189 | 0.86 | SIGMAR1 (1.00) | SIGMAR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280657-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280657-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | ELAVL1, ADH1A, NGF | SIGMAR1 423/4885TMEM97 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.